Cardiac iodine-123 metaiodobenzylguanidine ( 123I-MIBG) scintigraphy parameter predicts cardiac and cerebrovascular events in type 2 diabetic patients without structural heart disease

Circulation Journal

Volumn 76, Issue 2, 2012, Pages 399-404

  Yufu, Kunio ^a   Takahashi, Naohiko ^a   Okada, Norihiro ^a   Shinohara, Tetsuji ^a   Nakagawa, Mikiko ^a   Hara, Masahide ^a   Yoshimatsu, Hironobu ^a   Saikawa, Tetsunori ^a  

^a OITA UNIVERSITY   (Japan)

Author keywords

Autonomic nervous system; Cardiac 123I MIBG scintigraphy; Cardiovascular disease; Diabetes mellitus

Indexed keywords

(3 IODOBENZYL) GUANIDINE I 123; UNCLASSIFIED DRUG;

ADULT; ADVERSE OUTCOME; ARTICLE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CONGESTIVE HEART FAILURE; FEMALE; FOLLOW UP; HEART DEATH; HEART MUSCLE REVASCULARIZATION; HUMAN; INCIDENCE; JAPAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PREDICTION; PREDICTIVE VALUE; PROPORTIONAL HAZARDS MODEL; SCINTIGRAPHY; STROKE; SYMPATHETIC FUNCTION;

3-IODOBENZYLGUANIDINE; AGED; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HUMANS; IODINE RADIOISOTOPES; JAPAN; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIAL REVASCULARIZATION; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RADIONUCLIDE IMAGING; SENSITIVITY AND SPECIFICITY; STROKE;

EID: 84856291588     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-11-0905     Document Type: Article

References (28)

1. Nishimura T, Nakajima K, Kusuoka H, Yamashina A, Nishimura S. Prognostic study of risk stratification among Japanese patients with ischemic heart disease using gated myocardial perfusion SPECT: JACCESS study. Eur J Nucl Med Mol Imaging 2008; 35: 319-328.
2. Yamasaki Y, Nakajima K, Kusuoka H, Izumi T, Kashiwagi A, Kawamori R, et al. Prognostic value of gated myocardial perfusion imaging for asymptomatic patients with type 2 diabetes: The JACCESS 2 investigation. Diabetes Care 2010; 33: 2320-2326.
3. Wieland DM, Brown LE, Rogers WL, Worthington KC, Wu JL, Clinthorne NH, et al. Myocardial imaging with a radioiodinated norepinephrine storage analog. J Nucl Med 1981; 22: 22-31.
4. Henderson EB, Kahn JK, Corbett JR, Jansen DE, Pippin JJ, Kulkarni P, et al. Abnormal I-123 metaiodobenzylguanidine myocardial washout and distribution may reflect myocardial adrenergic derangement in patients with congestive cardiomyopathy. Circulation 1988; 78: 1192-1199.
5. Nagamachi S, Fujita S, Nishii R, Futami S, Tamura S, Mizuta M, et al. Prognostic value of cardiac I-123 metaiodobenzylguanidine imaging in patients with non-insulin-dependent diabetes mellitus. J Nucl Cardiol 2006; 13: 34-42.
6. Cohen-Solal A, Esanu Y, Logeart D, Pessione F, Dubois C, Dreyfus G, et al. Cardiac metaiodobenzylguanidine uptake in patients with moderate chronic heart failure: Relationship with peak oxygen uptake and prognosis. Am Coll Cardiol 1999; 33: 759-766.
7. Ogita H, Shimonagata T, Fukunami M, Kumagai K, Yamada T, Asano Y, et al. Prognostic significance of cardiac (123)I metaiodobenzylguanidine imaging for mortality and morbidity in patients with chronic heart failure: A prospective study. Heart 2001; 86: 656-660.
8. Kyuma M, Nakata T, Hashimoto A, Nagao K, Sasao H, Takahashi T, et al. Incremental prognostic implications of brain natriuretic peptide, cardiac sympathetic nerve innervation, and noncardiac disorders in patients with heart failure. J Nucl Med 2004; 45: 155-163.
9. Arimoto T, Takeishi Y, Niizeki T, Nozaki N, Hirono O, Watanabe T, et al. Cardiac sympathetic denervation and ongoing myocardial damage for prognosis in early stages of heart failure. J Card Fail 2007; 13: 34-41.
10. Nakata T, Wakabayashi T, Kyuma M, Takahashi T, Tsuchihashi K, Shimamoto K. Cardiac metaiodobenzylguanidine activity can predict the long-term efficacy of angiotensin-converting enzyme inhibitors and/or beta-adrenoceptor blockers in patients with heart failure. Eur J Nucl Med Mol Imaging 2005; 32: 186-194.
11. Fujimoto S, Inoue A, Hisatake S, Yamashina S, Yamashina H, Nakano H, et al. Usefulness of meta-[123I]iodobenzylguanidine myocardial scintigraphy for predicting cardiac events in patients with dilated cardiomyopathy who receive long-term beta blocker treatment. Nucl Med Commun 2005; 26: 97-102.
12. 123I-MIBG imaging in patients with stabilized chronic heart failure and reduced left ventricular ejection fraction. J Nucl Med 2008; 49: 907-914.
13. Kasama S, Toyama T, Sumino H, Kumakura H, Takayama Y, Minami K, et al. Serial cardiac 123I-metaiodobenzylguanidine scintigraphic studies are more useful for predicting cardiac death than one-time scan in patients with chronic heart failure: Sub-analysis of our previous report. Nucl Med Commun 2010; 31: 807-813.
14. Kuzuya T, Nakagawa S, Satoh J, Kanazawa Y, Iwamoto Y, Kobayashi M, et al. Report of the Committee on the Classification and Diagnostic Criteria of Diabetes Mellitus. Diabetes Res Clin Pract 2002; 55: 65-85.
15. Liao D, Sloan RP, Cascio WE, Folsom AR, Liese AD, Evans GW, et al. Multiple metabolic syndrome is associated with lower heart rate variability: The Atherosclerosis Risk in Communities Study. Diabetes Care 1998; 21: 2116-2122.
16. Hakoda M, Masunari N, Yamada M, Fujiwara S, Suzuki G, Kodama K, et al. Serum uric acid concentration as a risk factor for cardiovascular mortality. J Rheumatol 2005; 32: 906-912.
17. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Am J Kidney Dis 2002; 39: S1-S266.
18. Takahashi N, Nakagawa M, Saikawa T, Ooie T, Yufu K, Shigematsu S, et al. Effect of essential hypertension on cardiac autonomic function in type 2 diabetic patients. J Am Coll Cardiol 2001; 38: 232-237.
19. 123I-MIBG myocardial scintigraphy in diabetic patients: Relationship with 201Tl uptake and cardiac autonomic function. Ann Nucl Med 1998; 12: 323-331.
20. Okada N, Takahashi N, Yufu K, Murozono Y, Wakisaka O, Shinohara T, et al. Baroreflex sensitivity predicts cardiovascular events in patients with type 2 diabetes mellitus without structural heart disease. Circ J 2010; 74: 1379-1383.
21. Yufu K, Takahashi N, Okada N, Wakisaka O, Shinohara T, Nakagawa M, et al. Gender difference in baroreflex sensitivity to predict cardiac and cerebrovascular events in type 2 diabetic patients. Circ J 2011; 75: 1418-1423.
22. Matsuo S, Nakajima K, Yamasaki Y, Kashiwagi A, Nishimura T. Prognostic value of normal stress myocardial perfusion imaging and ventricular function in Japanese asymptomatic patients with type 2 diabetes: A study based on the J-ACCESS-2 database. Circ J 2010; 74: 1916-1921.
23. Anan F, Masaki T, Shinohara T, Yufu K, Takahashi N, Nakagawa M, et al. White matter lesions are associated with the results of 123Imetaiodobenzylguanidine myocardial scintigraphy in type 2 diabetes mellitus patients. Metabolism 2009; 58: 696-703.
24. Mayhan WG, Simmons LK, Sharpe GM. Mechanism of impaired responses of cerebral arterioles during diabetes mellitus. Am J Physiol 1991; 260: H319-H326.
25. Morita-Tsuzuki Y, Hardebo JE, Bouskela E. Interaction between cerebrovascular sympathetic, parasympathetic and sensory nerves in blood flow regulation. J Vasc Res 1993; 30: 263-271.
26. Schnell O. Cardiac sympathetic innervation and blood flow regulation of the diabetic heart. Diabetes Metab Res Rev 2001; 17: 243-245.
27. Scholte AJ, Schuijf JD, Kharagjitsingh AV, Dibbets-Schneider P, Stokkel MP, van der Wall EE, et al. Prevalence and predictors of an abnormal stress myocardial perfusion study in asymptomatic patients with type 2 diabetes mellitus. Eur J Nucl Med Mol Imaging 2009; 36: 567-575.
28. Jacqueminet S, Barthelemy O, Rouzet F, Isnard R, Halbron M, Bouzamondo A, et al. A randomized study comparing isotope and echocardiography stress testing in the screening of silent myocardial ischaemia in type 2 diabetic patients. Diabetes Metab 2010; 36: 463-469.